Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Assessing and Counseling the Older Driver: A Concise Review for the Generalist Clinician.

Hill LJN, Pignolo RJ, Tung EE.

Mayo Clin Proc. 2019 Aug;94(8):1582-1588. doi: 10.1016/j.mayocp.2019.03.023. Review.

PMID:
31378232
2.

Creating the Next Generation of Translational Geroscientists.

Newman JC, Sokoloski JL, Robbins PD, Niedernhofer LJ, Reed MJ, Wei J, Austad SN, Barzilai N, Cohen HJ, Kuchel GA, Kirkland JL, Pignolo RJ.

J Am Geriatr Soc. 2019 Jul 9. doi: 10.1111/jgs.16055. [Epub ahead of print]

PMID:
31287934
3.

Molecular characterization of known and novel ACVR1 variants in phenotypes of aberrant ossification.

Gupta A, Zimmermann MT, Wang H, Broski SM, Sigafoos AN, Macklin SK, Urrutia RA, Clark KJ, Atwal PS, Pignolo RJ, Klee EW.

Am J Med Genet A. 2019 Sep;179(9):1764-1777. doi: 10.1002/ajmg.a.61274. Epub 2019 Jun 26.

PMID:
31240838
4.

Correction to: Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes.

Pignolo RJ, Baujat G, Brown MA, De Cunto C, Di Rocco M, Hsiao EC, Keen R, Al Mukaddam M, Sang KLQ, Wilson A, White B, Grogan DR, Kaplan FS.

Orphanet J Rare Dis. 2019 May 23;14(1):113. doi: 10.1186/s13023-019-1096-3.

5.

Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes.

Pignolo RJ, Baujat G, Brown MA, De Cunto C, Di Rocco M, Hsiao EC, Keen R, Al Mukaddam M, Sang KLQ, Wilson A, White B, Grogan DR, Kaplan FS.

Orphanet J Rare Dis. 2019 May 3;14(1):98. doi: 10.1186/s13023-019-1068-7. Erratum in: Orphanet J Rare Dis. 2019 May 23;14(1):113.

6.

Targeting Cell Senescence for the Treatment of Age-Related Bone Loss.

Pignolo RJ, Samsonraj RM, Law SF, Wang H, Chandra A.

Curr Osteoporos Rep. 2019 Apr;17(2):70-85. doi: 10.1007/s11914-019-00504-2. Review.

PMID:
30806947
7.

Exceptional Human Longevity.

Pignolo RJ.

Mayo Clin Proc. 2019 Jan;94(1):110-124. doi: 10.1016/j.mayocp.2018.10.005. Epub 2018 Dec 10. Review.

PMID:
30545477
8.

Potential role of senescence in radiation-induced damage of the aged skeleton.

Chandra A, Park SS, Pignolo RJ.

Bone. 2019 Mar;120:423-431. doi: 10.1016/j.bone.2018.12.006. Epub 2018 Dec 10.

PMID:
30543989
9.

Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP).

Hsiao EC, Di Rocco M, Cali A, Zasloff M, Al Mukaddam M, Pignolo RJ, Grunwald Z, Netelenbos C, Keen R, Baujat G, Brown MA, Cho TJ, De Cunto C, Delai P, Haga N, Morhart R, Scott C, Zhang K, Diecidue RJ, Friedman CS, Kaplan FS, Eekhoff EMW.

Br J Clin Pharmacol. 2019 Jun;85(6):1199-1207. doi: 10.1111/bcp.13777. Epub 2018 Nov 6. Review.

10.

Heterotopic Ossification: The Keys to the Kingdom.

Kaplan FS, Pignolo RJ, Shore EM.

Bone. 2018 Apr;109:1-2. doi: 10.1016/j.bone.2018.03.001. No abstract available.

PMID:
29567209
11.

Serum vitamin C levels modulate the lifespan and endoplasmic reticulum stress response pathways in mice synthesizing a nonfunctional mutant WRN protein.

Aumailley L, Dubois MJ, Brennan TA, Garand C, Paquet ER, Pignolo RJ, Marette A, Lebel M.

FASEB J. 2018 Jul;32(7):3623-3640. doi: 10.1096/fj.201701176R. Epub 2018 Feb 8.

12.

A case report of mesenteric heterotopic ossification: Histopathologic and genetic findings.

Amalfitano M, Fyfe B, Thomas SV, Egan KP, Xu M, Smith AG, Kaplan FS, Shore EM, Pignolo RJ.

Bone. 2018 Apr;109:56-60. doi: 10.1016/j.bone.2018.01.006. Epub 2018 Jan 7.

PMID:
29320714
13.

Circulating osteogentic precursor cells in non-hereditary heterotopic ossification.

Egan KP, Duque G, Keenan MA, Pignolo RJ.

Bone. 2018 Apr;109:61-64. doi: 10.1016/j.bone.2017.12.028. Epub 2018 Jan 3.

PMID:
29305336
14.

ECSIT links TLR and BMP signaling in FOP connective tissue progenitor cells.

Wang H, Behrens EM, Pignolo RJ, Kaplan FS.

Bone. 2018 Apr;109:201-209. doi: 10.1016/j.bone.2017.12.024. Epub 2017 Dec 27.

PMID:
29288875
15.

Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.

Kaplan FS, Zeitlin L, Dunn SP, Benor S, Hagin D, Al Mukaddam M, Pignolo RJ.

Bone. 2018 Apr;109:281-284. doi: 10.1016/j.bone.2017.12.011. Epub 2017 Dec 11.

PMID:
29241828
16.

Prevalence and risk factors for kidney stones in fibrodysplasia ossificans progressiva.

Gupta RR, Delai PLR, Glaser DL, Rocke DM, Al Mukaddam M, Pignolo RJ, Kaplan FS.

Bone. 2018 Apr;109:120-123. doi: 10.1016/j.bone.2017.12.010. Epub 2017 Dec 11.

PMID:
29241827
17.

Histopathology of periarticular non-hereditary heterotopic ossification.

Foley KL, Hebela N, Keenan MA, Pignolo RJ.

Bone. 2018 Apr;109:65-70. doi: 10.1016/j.bone.2017.12.006. Epub 2017 Dec 7.

PMID:
29225159
18.

Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP).

Kaplan FS, Pignolo RJ, Al Mukaddam MM, Shore EM.

Expert Opin Orphan Drugs. 2017;5(4):291-294. doi: 10.1080/21678707.2017.1304211. Epub 2017 Mar 17. No abstract available.

19.
20.

Corrigendum: Targeting cellular senescence prevents age-related bone loss in mice.

Farr JN, Xu M, Weivoda MM, Monroe DG, Fraser DG, Onken JL, Negley BA, Sfeir JG, Ogrodnik MB, Hachfeld CM, LeBrasseur NK, Drake MT, Pignolo RJ, Pirtskhalava T, Tchkonia T, Oursler MJ, Kirkland JL, Khosla S.

Nat Med. 2017 Nov 7;23(11):1384. doi: 10.1038/nm1117-1384c.

PMID:
29117174
21.

Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva.

Wentworth KL, Bigay K, Chan TV, Ho JP, Morales BM, Connor J, Brooks E, Shahriar Salamat M, Sanchez HC, Wool G, Pignolo RJ, Kaplan FS, Hsiao EC.

Bone. 2018 Apr;109:104-110. doi: 10.1016/j.bone.2017.10.009. Epub 2017 Oct 13.

PMID:
29033382
22.

Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP).

Lindborg CM, Brennan TA, Wang H, Kaplan FS, Pignolo RJ.

Bone. 2018 Apr;109:153-157. doi: 10.1016/j.bone.2017.09.016. Epub 2017 Sep 28.

PMID:
28963080
23.

Clinical staging of Fibrodysplasia Ossificans Progressiva (FOP).

Pignolo RJ, Kaplan FS.

Bone. 2018 Apr;109:111-114. doi: 10.1016/j.bone.2017.09.014. Epub 2017 Sep 21.

PMID:
28943457
24.

Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis.

Chandra A, Wang L, Young T, Zhong L, Tseng WJ, Levine MA, Cengel K, Liu XS, Zhang Y, Pignolo RJ, Qin L.

FASEB J. 2018 Jan;32(1):52-62. doi: 10.1096/fj.201700375R. Epub 2017 Aug 31.

25.

Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP).

Brennan TA, Lindborg CM, Bergbauer CR, Wang H, Kaplan FS, Pignolo RJ.

Bone. 2018 Apr;109:259-266. doi: 10.1016/j.bone.2017.08.023. Epub 2017 Aug 26.

PMID:
28851540
26.

Targeting cellular senescence prevents age-related bone loss in mice.

Farr JN, Xu M, Weivoda MM, Monroe DG, Fraser DG, Onken JL, Negley BA, Sfeir JG, Ogrodnik MB, Hachfeld CM, LeBrasseur NK, Drake MT, Pignolo RJ, Pirtskhalava T, Tchkonia T, Oursler MJ, Kirkland JL, Khosla S.

Nat Med. 2017 Sep;23(9):1072-1079. doi: 10.1038/nm.4385. Epub 2017 Aug 21. Erratum in: Nat Med. 2017 Nov 7;23 (11):1384.

27.

Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable.

Al Mukaddam M, Rajapakse CS, Pignolo RJ, Kaplan FS, Smith SE.

Bone. 2018 Apr;109:147-152. doi: 10.1016/j.bone.2017.08.011. Epub 2017 Aug 16.

PMID:
28822792
28.

Acute unilateral hip pain in fibrodysplasia ossificans progressiva (FOP).

Kaplan FS, Al Mukaddam M, Pignolo RJ.

Bone. 2018 Apr;109:115-119. doi: 10.1016/j.bone.2017.08.009. Epub 2017 Aug 16.

PMID:
28822791
29.

Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.

Kaplan FS, Andolina JR, Adamson PC, Teachey DT, Finklestein JZ, Ebb DH, Whitehead B, Jacobs B, Siegel DM, Keen R, Hsiao E, Pignolo RJ.

Bone. 2018 Apr;109:276-280. doi: 10.1016/j.bone.2017.07.019. Epub 2017 Jul 20.

PMID:
28736245
30.

Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva (FOP).

Pignolo RJ, Durbin-Johnson BP, Rocke DM, Kaplan FS.

Bone. 2018 Apr;109:124-133. doi: 10.1016/j.bone.2017.06.009. Epub 2017 Jun 13.

PMID:
28627475
31.

International physician survey on management of FOP: a modified Delphi study.

Di Rocco M, Baujat G, Bertamino M, Brown M, De Cunto CL, Delai PLR, Eekhoff EMW, Haga N, Hsiao E, Keen R, Morhart R, Pignolo RJ, Kaplan FS.

Orphanet J Rare Dis. 2017 Jun 12;12(1):110. doi: 10.1186/s13023-017-0659-4.

32.

Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP).

Kaplan FS, Al Mukaddam M, Pignolo RJ.

Bone. 2018 Apr;109:158-161. doi: 10.1016/j.bone.2017.06.005. Epub 2017 Jun 6.

PMID:
28600150
33.

Age, gender, and percentage of circulating osteoprogenitor (COP) cells: The COP Study.

Gunawardene P, Al Saedi A, Singh L, Bermeo S, Vogrin S, Phu S, Suriyaarachchi P, Pignolo RJ, Duque G.

Exp Gerontol. 2017 Oct 1;96:68-72. doi: 10.1016/j.exger.2017.06.004. Epub 2017 Jun 6.

PMID:
28599951
34.

The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call.

Towler OW, Shore EM, Xu M, Bamford A, Anderson I, Pignolo RJ, Kaplan FS.

Eur J Med Genet. 2017 Jul;60(7):399-402. doi: 10.1016/j.ejmg.2017.04.013. Epub 2017 May 1.

PMID:
28473268
35.

A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP).

Kaplan FS, Al Mukaddam M, Pignolo RJ.

Bone. 2017 Aug;101:123-128. doi: 10.1016/j.bone.2017.04.015. Epub 2017 Apr 29.

PMID:
28465250
36.

Gsα Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and β-Catenin Pathways.

Ramaswamy G, Kim H, Zhang D, Lounev V, Wu JY, Choi Y, Kaplan FS, Pignolo RJ, Shore EM.

Sci Rep. 2017 Mar 24;7:45140. doi: 10.1038/srep45140.

37.

Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva.

Rajapakse CS, Lindborg C, Wang H, Newman BT, Kobe EA, Chang G, Shore EM, Kaplan FS, Pignolo RJ.

Acad Radiol. 2017 Mar;24(3):321-327. doi: 10.1016/j.acra.2016.10.010. Epub 2016 Dec 15.

38.

Identification of Senescent Cells in the Bone Microenvironment.

Farr JN, Fraser DG, Wang H, Jaehn K, Ogrodnik MB, Weivoda MM, Drake MT, Tchkonia T, LeBrasseur NK, Kirkland JL, Bonewald LF, Pignolo RJ, Monroe DG, Khosla S.

J Bone Miner Res. 2016 Nov;31(11):1920-1929. doi: 10.1002/jbmr.2892. Epub 2016 Oct 24.

39.

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE.

J Bone Miner Res. 2016 Oct;31(10):1910. doi: 10.1002/jbmr.2918. Epub 2016 Jul 26. No abstract available.

40.

Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.

Wang H, Lindborg C, Lounev V, Kim JH, McCarrick-Walmsley R, Xu M, Mangiavini L, Groppe JC, Shore EM, Schipani E, Kaplan FS, Pignolo RJ.

J Bone Miner Res. 2016 Sep;31(9):1652-65. doi: 10.1002/jbmr.2848. Epub 2016 Apr 20.

41.

The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.

Pignolo RJ, Bedford-Gay C, Liljesthröm M, Durbin-Johnson BP, Shore EM, Rocke DM, Kaplan FS.

J Bone Miner Res. 2016 Mar;31(3):650-6. doi: 10.1002/jbmr.2728. Epub 2015 Nov 14.

42.

Aging alters bone-fat reciprocity by shifting in vivo mesenchymal precursor cell fate towards an adipogenic lineage.

Singh L, Brennan TA, Russell E, Kim JH, Chen Q, Brad Johnson F, Pignolo RJ.

Bone. 2016 Apr;85:29-36. doi: 10.1016/j.bone.2016.01.014. Epub 2016 Jan 19.

43.

Granting immunity to FOP and catching heterotopic ossification in the Act.

Kaplan FS, Pignolo RJ, Shore EM.

Semin Cell Dev Biol. 2016 Jan;49:30-6. doi: 10.1016/j.semcdb.2015.12.013. Epub 2015 Dec 17. Review.

44.

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE.

J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708. Review. Erratum in: J Bone Miner Res. 2016 Oct;31(10 ):1910.

45.

Clopidogrel Enhances Mesenchymal Stem Cell Proliferation Following Periodontitis.

Coimbra LS, Steffens JP, Alsadun S, Albiero ML, Rossa C Jr, Pignolo RJ, Spolidorio LC, Graves DT.

J Dent Res. 2015 Dec;94(12):1691-7. doi: 10.1177/0022034515598273. Epub 2015 Jul 28.

46.

Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.

Kaplan FS, Kobori JA, Orellana C, Calvo I, Rosello M, Martinez F, Lopez B, Xu M, Pignolo RJ, Shore EM, Groppe JC.

Am J Med Genet A. 2015 Oct;167A(10):2265-71. doi: 10.1002/ajmg.a.37205. Epub 2015 Jun 11.

47.

Conservation of pro-longevity genes among mammals.

Lindborg CM, Propert KJ, Pignolo RJ.

Mech Ageing Dev. 2015 Mar;146-148:23-7. doi: 10.1016/j.mad.2015.03.004. Epub 2015 Mar 21.

48.

The immunological contribution to heterotopic ossification disorders.

Convente MR, Wang H, Pignolo RJ, Kaplan FS, Shore EM.

Curr Osteoporos Rep. 2015 Apr;13(2):116-24. doi: 10.1007/s11914-015-0258-z. Review.

49.

Progressive osseous heteroplasia: diagnosis, treatment, and prognosis.

Pignolo RJ, Ramaswamy G, Fong JT, Shore EM, Kaplan FS.

Appl Clin Genet. 2015 Jan 30;8:37-48. doi: 10.2147/TACG.S51064. eCollection 2015. Review.

50.

Clinical Utility Gene Card for: Fibrodysplasia ossificans progressiva.

Bravenboer N, Micha D, Triffit JT, Bullock AN, Ravazollo R, Bocciardi R, di Rocco M, Netelenbos JC, Ten Dijke P, Sánchez-Duffhues G, Kaplan FS, Shore EM, Pignolo RJ, Seemann P, Ventura F, Beaujat G, Eekhoff EM, Pals G.

Eur J Hum Genet. 2015 Oct;23(10). doi: 10.1038/ejhg.2014.274. Epub 2015 Jan 21. No abstract available.

Supplemental Content

Loading ...
Support Center